» Articles » PMID: 36685768

Degeneration of Retina-brain Components and Connections in Glaucoma: Disease Causation and Treatment Options for Eyesight Preservation

Overview
Date 2023 Jan 23
PMID 36685768
Authors
Affiliations
Soon will be listed here.
Abstract

Eyesight is the most important of our sensory systems for optimal daily activities and overall survival. Patients who experience visual impairment due to elevated intraocular pressure (IOP) are often those afflicted with primary open-angle glaucoma (POAG) which slowly robs them of their vision unless treatment is administered soon after diagnosis. The hallmark features of POAG and other forms of glaucoma are damaged optic nerve, retinal ganglion cell (RGC) loss and atrophied RGC axons connecting to various brain regions associated with receipt of visual input from the eyes and eventual decoding and perception of images in the visual cortex. Even though increased IOP is the major risk factor for POAG, the disease is caused by many injurious chemicals and events that progress slowly within all components of the eye-brain visual axis. Lowering of IOP mitigates the damage to some extent with existing drugs, surgical and device implantation therapeutic interventions. However, since multifactorial degenerative processes occur during aging and with glaucomatous optic neuropathy, different forms of neuroprotective, nutraceutical and electroceutical regenerative and revitalizing agents and processes are being considered to combat these eye-brain disorders. These aspects form the basis of this short review article.

Citing Articles

Stable Gastric Pentadecapeptide BPC 157-Possible Novel Therapy of Glaucoma and Other Ocular Conditions.

Sikiric P, Kokot A, Kralj T, Zlatar M, Masnec S, Lazic R Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513963 PMC: 10385428. DOI: 10.3390/ph16071052.

References
1.
Futakuchi A, Morimoto T, Ikeda Y, Tanihara H, Inoue T . Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study. Sci Rep. 2020; 10(1):10308. PMC: 7316751. DOI: 10.1038/s41598-020-66928-4. View

2.
McMonnies C . Reactive oxygen species, oxidative stress, glaucoma and hyperbaric oxygen therapy. J Optom. 2017; 11(1):3-9. PMC: 5777925. DOI: 10.1016/j.optom.2017.06.002. View

3.
Abu-Hassan D, Li X, Ryan E, Acott T, Kelley M . Induced pluripotent stem cells restore function in a human cell loss model of open-angle glaucoma. Stem Cells. 2014; 33(3):751-61. PMC: 4359625. DOI: 10.1002/stem.1885. View

4.
Buffault J, Labbe A, Hamard P, Brignole-Baudouin F, Baudouin C . The trabecular meshwork: Structure, function and clinical implications. A review of the literature. J Fr Ophtalmol. 2020; 43(7):e217-e230. DOI: 10.1016/j.jfo.2020.05.002. View

5.
Stothert A, Fontaine S, Sabbagh J, Dickey C . Targeting the ER-autophagy system in the trabecular meshwork to treat glaucoma. Exp Eye Res. 2015; 144:38-45. PMC: 4698052. DOI: 10.1016/j.exer.2015.08.017. View